Posted by Michael Wonder on 19 Jan 2024
Voydeya (danicopan) granted first ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy
19 January 2024 - Approval of first in class, oral, factor D inhibitor based on ALPHA Phase 3 trial in a subset of patients with paroxysmal nocturnal haemoglobinuria.
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria.
